Christiansen MK, Haugaa KH, Svensson A, et al. - Researchers explored the factors predictive of as well as the use of ventricular tachycardia (VT) ablation and assessed the postprocedural result in arrhythmogenic right ventricular cardiomyopathy (ARVC) patients. They examined 435 patients identified from the Nordic ARVC registry with 220 probands with definite ARVC as per the 2010 task force criteria and 215 mutation-carrying relatives recognized via cascade screening. The cumulative use of VT ablation was estimated to be 4% after 1 year and 11% after 10 years. The risk of recurrent arrhythmias in patients receiving ablation was estimated to be 59% at 1-year post-procedure and 74% at 5 years following the procedure. The factors that were related to an unfavorable outcome were young age, the use of several antiarrhythmic drugs and inducibility to VT post-ablation. Findings revealed the development of a clinical indication for VT ablation within 10 years in 20% of ARVC probands. In contrast, such a need was not seen in mutation-carrying relatives. A substantial risk of recurrence was observed despite a reduced burden of ventricular arrhythmias following ablation.